Can ketamine therapy overcome treatment-resistant depression in Alzheimer's disease and older adults? Preclinical and clinical evidence.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie July 1, 2025 Altamura Mario, Leccisotti Ivana, Moretti Maria Claudia et al. 5 citations
Treatment-resistant depression (TRD) presents substantial clinical challenges, particularly in patients with Alzheimer's disease (AD) and older adults experiencing late-life depression. Traditional monoaminergic therapies often fail in this population due to neurodegenerative changes that impact receptor dynamics and neurotransmitter systems. Emerging evidence suggests that N-methyl-D-aspartate...
DOI: 10.1016/j.biopha.2025.118199 (opens in new tab)
Full text (opens in new tab)
Esketamine
Treatment-resistant depression
Alzheimer’s disease
Elderly population
+6